$236 Million is the total value of Fairmount Funds Management LLC's 17 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 21.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INSM | Buy | INSMED INC | $33,965,000 | +22.0% | 1,056,797 | +4.6% | 14.39% | +15.9% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $26,723,000 | -5.8% | 647,833 | +10.6% | 11.32% | -10.6% |
| Buy | TRILLIUM THERAPEUTICS INC | $22,142,000 | +84.5% | 1,558,181 | +5.1% | 9.38% | +75.2% | |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $20,550,000 | -9.5% | 1,455,395 | -3.3% | 8.70% | -14.0% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $19,650,000 | +18.5% | 596,890 | -1.2% | 8.32% | +12.6% |
| ZGNX | Buy | ZOGENIX INC | $18,950,000 | -27.8% | 1,056,875 | +8.7% | 8.03% | -31.4% |
| AXSM | Buy | AXSOME THERAPEUTICS INC | $15,682,000 | -11.8% | 220,098 | +1.9% | 6.64% | -16.3% |
| UMRX | New | UNUM THERAPEUTICS INC | $13,716,000 | – | 6,235,903 | +100.0% | 5.81% | – |
| ALLK | Sell | ALLAKOS INC | $13,412,000 | +4.5% | 164,662 | -7.8% | 5.68% | -0.8% |
| ARGX | Sell | ARGENX SEsponsored adr | $13,113,000 | +15.4% | 49,950 | -1.0% | 5.55% | +9.6% |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $10,254,000 | -17.0% | 702,351 | +7.7% | 4.34% | -21.2% |
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $7,427,000 | -13.0% | 162,236 | -4.5% | 3.15% | -17.3% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $6,350,000 | -34.6% | 1,508,237 | +7.5% | 2.69% | -37.9% |
| MRTX | New | MIRATI THERAPEUTICS INC | $5,812,000 | – | 35,000 | +100.0% | 2.46% | – |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $4,473,000 | -65.0% | 372,748 | -51.6% | 1.90% | -66.8% |
| KNSA | Buy | KINIKSA PHARMACEUTICALS LTD | $3,259,000 | -36.1% | 212,746 | +6.3% | 1.38% | -39.3% |
| VRNA | New | VERONA PHARMA PLCsponsored ads | $624,000 | – | 100,000 | +100.0% | 0.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.